- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02480842
Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction
Randomized Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Methods:
Patients will be recruited just after surgery scheduling. They will undergo preoperative evaluation one week before the surgery on average. At this moment, preoperative analysis will be conducted with personal data and medical history. Patients will undergo new assessments 07, 15, 30, 60, 90 and 180 days after surgery, periods that will be described as PO 07, PO 15, PO 30, PO 60, PO 90 and PO 180.
All patients will receive standard physiotherapy treatment for women undergoing breast reconstruction from Physical Therapy Sector of Mastology Discipline of the Department of Gynecology of Federal University of São Paulo. The protocol consists of early exercise, limited to 90° of shoulder range of motion (ROM), starting the day after the surgery and repeated 7 days after surgery.
After 15 days of surgery, the patients will be randomized into two treatment protocols.
However, because of the existence of different types of reconstructive surgery, randomization will performed from two groups:
- Alloplastic group: patients who will undergo reconstruction with tissue expander or breast implant
- Oncoplastic Group: patients who will undergo mammaplasty and / or contralateral symmetrization
Computer random sequence will be used for randomization, in which each group will be randomized to Group A or Group B.
- Subgroup A: Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain.
- Subgroup B: Patient will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction
At the end of randomization there will be four subgroups: alloplastic A, alloplastic B, oncoplastic A and oncoplastic B
Outcomes:
Shoulder range of motion:
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation. The movements will be performed actively. The patient will be positioned in the sitting position. To assess shoulder flexion, the upper limb will be in neutral position with elbow extension. Patient will be asked to raise the arm forward, close to the body. To assess extension, the arm will be positioned with 90° of elbow flexion and the patient will be asked to take the arm back. For adduction, the patient will be with 90° of shoulder flexion with the palm down and patient will be told to move the arm medially. For the study of the upper limb abduction, the limb will be in supination and elbow extension and the patient will be asked to raise the arm to the side, along the trunk line toward the ear. For the evaluation of internal rotation and external rotation the upper limb will be placed in 90° of shoulder abduction and 90° of elbow flexion. The patient will be asked to rotate the shoulder internally and externally, respectively.
Pain:
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain. The patient will be asked if there is pain at the moment of evaluation , and to describe the place and the degree of the pain.
Upper limbs function:
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used. It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms. It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities. The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application. The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
Dehiscence:
Dehiscence wil be assessed by inspection and palpation. It will be described "presence" or "absence" of dehiscence and its location. The wound conditions will be described, with observation of necrosis and infection. Signs of infection such as redness, hyperthermia and secretion will be reported. The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape). Photographic record of dehiscence will be done, for better analysis and comparison of evolution. A Nikon Coolpix S3000 camera will be used.
- Seroma:
The seroma evaluation will be performed by inspection and palpation. There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
São Paulo, Brasil, 04024002
- Federal University of São Paulo
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women with breast cancer, who will be submitted to breast surgery (radical or conservative), followed by immediate reconstruction: alloplastic (tissue expander or breast implant) or oncoplastic (breast reduction or contralateral symmetrization).
Exclusion Criteria:
- Patients that will be submitted to bilateral oncology surgery, reconstruction with autologous tissue or breast surgery without reconstruction. Patients with motor or neurological deficits prior to surgery, with cognitive impairment and those that do not accept to participate.
- Patients who need to undergo new surgical procedures during the postoperative follow-up period and those who do not appear to postoperative evaluations
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Alloplastic group A
After randomization (15 days after surgery): - Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain. |
|
|
Eksperimentell: Alloplastic group B
After randomization (15 days after surgery): - Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction |
|
|
Eksperimentell: Oncoplastic group A
After randomization (15 days after surgery): - Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain. |
|
|
Eksperimentell: Oncoplastic group B
After randomization (15 days after surgery): - Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 07 days after surgery assessment
Tidsramme: One week before surgery on average and 07 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 07 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 15 days after surgery assessment
Tidsramme: One week before surgery on average and 15 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 15 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Tidsramme: One week before surgery on average and 30 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 30 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 60 days after surgery assessment
Tidsramme: One week before surgery on average and 60 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 60 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Tidsramme: One week before surgery on average and 90 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 90 days after surgery
|
|
Change in shoulder range of motion from preoperative assessment (one week before surgery on average) at 180 days after surgery assessment
Tidsramme: One week before surgery on average and 180 days after surgery
|
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction, abduction, internal rotation and external rotation.
The movements will be performed actively.
|
One week before surgery on average and 180 days after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 07 days after surgery assessment
Tidsramme: One week before surgery on average and 07 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 07 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 15 days after surgery assessment
Tidsramme: One week before surgery on average and 15 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 15 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Tidsramme: One week before surgery on average and 30 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 30 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 60 days after surgery assessment
Tidsramme: One week before surgery on average and 60 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 60 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Tidsramme: One week before surgery on average and 90 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 90 days after surgery
|
|
Change in self reported pain intensity from preoperative assessment (one week before surgery on average) at 180 days after surgery assessment
Tidsramme: One week before surgery on average and 180 days after surgery
|
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is no pain and ten is unbearable pain.
The patient will be asked if there is pain at the moment of evaluation, and to describe the place and the degree of the pain.
|
One week before surgery on average and 180 days after surgery
|
|
Change in upper limbs function from preoperative assessment (one week before surgery on average) at 30 days after surgery assessment
Tidsramme: One week before surgery on average and 30 days after surgery
|
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used.
It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms.
It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities.
The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application.
The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
|
One week before surgery on average and 30 days after surgery
|
|
Change in upper limbs function from preoperative assessment (one week before surgery on average) at 90 days after surgery assessment
Tidsramme: One week before surgery on average and 90 days after surgery
|
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire will be used.
It assesses the functional capacity in upper limb diseases and measures the skills to do certain activities, as well as the symptoms.
It consists of 30 self-administered questions and two optional modules, for sports or musical activities and work activities.
The 30 items evaluate the degree of difficulty in the performance of activities; the intensity of the symptoms of pain, weakness, stiffness and numbness; the commitment of social activities; the difficulty to sleep and psychological commitment by reference to the week preceding the instrument application.
The final score ranges from zero to one hundred, and the higher the score, the higher the upper limb dysfunction (arm, shoulder or hand).
|
One week before surgery on average and 90 days after surgery
|
|
Dehiscence at 07 days after surgery assessment
Tidsramme: 07 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
07 days after surgery
|
|
Dehiscence at 15 days after surgery assessment
Tidsramme: 15 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
15 days after surgery
|
|
Dehiscence at 30 days after surgery assessment
Tidsramme: 30 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
30 days after surgery
|
|
Dehiscence at 60 days after surgery assessment
Tidsramme: 60 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
60 days after surgery
|
|
Dehiscence at 90 days after surgery assessment
Tidsramme: 90 days after surgery
|
Dehiscence wil be assessed by inspection and palpation.
It will be described "presence" or "absence" of dehiscence and its location.
The wound conditions will be described, with observation of necrosis and infection.
Signs of infection such as redness, hyperthermia and secretion will be reported.
The size of dehiscence will be described: in relation to the amount of opening points, in case of several opened points; or in centimeters (assessed per tape).
Photographic record of dehiscence will be done, for better analysis and comparison of evolution.
|
90 days after surgery
|
|
Seroma at 07 days after surgery assessment
Tidsramme: 07 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
07 days after surgery
|
|
Seroma at 15 days after surgery assessment
Tidsramme: 15 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
15 days after surgery
|
|
Seroma at 30 days after surgery assessment
Tidsramme: 30 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
30 days after surgery
|
|
Seroma at 60 days after surgery assessment
Tidsramme: 60 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
60 days after surgery
|
|
Seroma at 90 days after surgery assessment
Tidsramme: 90 days after surgery
|
The seroma evaluation will be performed by inspection and palpation.
There will be description of "presence" or "absence" of seroma, location and the number of punctures made by the medical team and drained quantity, when necessary.
|
90 days after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FUSaoPaulo PT 3
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystneoplasmer
-
Guangzhou First People's HospitalFullført
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Technische Universität DresdenHar ikke rekruttert ennåMDS (myelodysplastisk syndrom) | CCUS klonal cytopeni av ubestemt betydning | MDS/Myeloproliferative Neoplasm (MPN) overlappingssyndrom | CHIPTyskland
-
Rabin Medical CenterFullførtDesmoid fibromatose | Desmoid | Desmoid fibromatose i huden | Desmoid Neoplasm of Chest Wall | Desmoid-svulst forårsaket av somatisk mutasjon | Aggressive fibromatoser | Fibromatose DesmoidIsrael
-
Chongqing Precision Biotech Co., LtdRekrutteringAML (akutt myeloid leukemi) | BPDCN (blastisk Plasmacytoid Dendritic Cell Neoplasm)Kina
-
Cancer Institute and Hospital, Chinese Academy...Rekruttering
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)FullførtAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Sør -Korea
Kliniske studier på Alloplastic free ROM
-
Silver Cloud HealthFullførtDepresjon | Understreke | AngstForente stater
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Fullført
-
Silver Cloud HealthTilbaketrukketDepresjon | Understreke | AngstIrland
-
Hebrew University of JerusalemUkjent
-
Duzce UniversityFullført
-
Necmettin Erbakan UniversityHar ikke rekruttert ennå
-
Golden Jubilee National HospitalUkjent
-
The Children's InstituteDuquesne University; Health Resources and Services Administration (HRSA)Fullført
-
Helse FordeWestern Norway University of Applied Sciences; Norwegian Nurses OrganisationUkjent